Butamirate

Butamirate is an orally active antitussive agent that acts centrally through the receptors in the brainstem. Butamirate also reduces the resistance in the airways by inhibiting bronchospasm and anti-inflammatory effect. Butamirate inhibits glioblastoma (GBM) growth and STAT3 activity. Butamirate can be used for the study of glioblastoma[1][2].

Product Specifications

CAS Number

[18109-80-3]

Product Name Alternative

CS-505

UNSPSC

12352005

Target

STAT

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/butamirate.html

Concentration

10mM

Purity

96.48

Solubility

DMSO : ≥ 250 mg/mL

Smiles

O=C(C(C1=CC=CC=C1)CC)OCCOCCN(CC)CC

Molecular Formula

C18H29NO3

Molecular Weight

307.43

References & Citations

[1]Płusa T. et al. Butamirate citrate in control of cough in respiratory tract inflammation. Pol Merkur Lekarski. 2017 Aug 21;43 (254) :69-74.|[2]Lee SJ, et al. Application of the antitussive agents oxelaidin and butamirate as anti-glioma agents. Sci Rep. 2021 May 12;11 (1) :10145.